Saturday, December 03, 2016 1:48:10 PM
decreasing volume and/or reduced metabolic activity over extended intervals of continued dosing were observed in several patients and one patient achieved a partial response.
single PR in Hodgkins @ .05 mg/Kg -68% relapsed
http://trilliumtherapeutics.com/investors/news/Press-Release-Details/2016/Trillium-Presents-Initial-Data-From-Ongoing-Study-of-TTI-621-In-Patients-With-Advanced-Hematologic-Malignancies-At-The-American-Society-of-Hematology-Annual-Meeting/default.aspx
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM